Compare Amphastar Pharmaceuticals Inc (AMPH) vs Angi Inc (ANGI) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

ANGI trades at $6.24, down 1.89% on the day, with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue of $1.03B in 2025 and net income of $43.83M, representing a 4.25% margin. Valuation metrics appear attractive with P/E of 14.85 and P/S of 0.27. Recent earnings showed a beat in Q1 2026 but misses in previous quarters, while analyst consensus price target sits at $9.20 with 33% buy ratings.

The stock presents a mixed outlook with attractive valuation multiples offset by declining revenue trends and ongoing legal investigations. Upside potential exists if the company's AI transition strategy succeeds, but risks include deteriorating core business metrics and multiple fraud investigations that could pressure shareholder value in the near term.